Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
Clinical trial NCT03668613 · COMPLETED
Trial details
- NCT number
- NCT03668613
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-29
- Primary completion
- 2019-09-19
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.